Your shopping cart is currently empty

MMAF Hydrochloride is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A. MMAF Hydrochloride is an effective tubulin polymerization inhibitor and is used as an antitumor compound.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | Inquiry | 1-2 weeks | 1-2 weeks | |
| 50 mg | Inquiry | 1-2 weeks | 1-2 weeks | |
| 100 mg | Inquiry | 1-2 weeks | 1-2 weeks |
| Description | MMAF Hydrochloride is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A. MMAF Hydrochloride is an effective tubulin polymerization inhibitor and is used as an antitumor compound. |
| In vitro | MMAF suppresses anaplastic large cell lymphoma Karpas 299, breast carcinoma H3396, renal cell carcinoma 786-O, and Caki-1 cells. It has IC50s of 119, 105, 257, and 200 nM in vitro cytotoxicity assay[4]. |
| In vivo | cAC10-L1-MMAF4 has an MTD of 50 mg/kg in mice and 15 mg/kg in rats, whereas the cAC10-L4-MMAF4 ADC is much less toxic, with MTDs of >150 mg/kg in mice and 90 mg/kg in rats. The maximum tolerated dose of MMAF (>16 mg/kg) in mice is much higher than that of MMAE (1 mg/kg) [4]. |
| Synonyms | Monomethylauristatin F Hydrochloride |
| Molecular Weight | 768.42 |
| Formula | C39H66ClN5O8 |
| Cas No. | 1415246-68-2 |
| Smiles | Cl.[H][C@](NC(=O)[C@@H](NC)C(C)C)(C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)C(O)=O)OC |
| Relative Density. | no data available |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||
| Solubility Information | DMSO: 27 mg/mL (35.14 mM), Sonication and heating are recommended. | |||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 2 mg/mL (2.6 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.